SFO-PG-20 is a pharma-grade sucroferric oxyhydroxide active pharmaceutical ingredient supplied as a reddish-brown powder for oral tablet, capsule, granule, and oral suspension manufacturing. The material is a polynuclear iron(III)-oxyhydroxide network stabilized by sucrose and starch; surface hydroxyl groups exchange with dietary phosphate in the gastrointestinal tract. The reference oral chewable tablet contains 500 mg elemental iron as 2500 mg sucroferric oxyhydroxide, corresponding to a nominal iron content of 20% w/w. The API is manufactured under ICH Q7 active substance guidance and controlled under ICH Q3C residual solvent and ICH Q3D elemental impurity frameworks. The labelled starting dose of the reference product is 500 mg iron three times daily with meals; tablets are chewed or crushed rather than swallowed whole to expose the active surface to dietary phosphate.

The iron-oxygen network is not a simple hydrated iron oxide; the sucrose and starch stabilizers inhibit conversion to crystalline goethite or hematite during synthesis and drying. This inhibition maintains a broad, poorly ordered oxyhydroxide surface with high phosphate-binding capacity per unit weight of iron. Phosphate binding occurs by ligand exchange in which phosphate ions displace coordinated water or hydroxyl groups; binding is low under strongly acidic conditions and increases as pH rises toward the weakly acidic and neutral environment of the duodenum and proximal jejunum. The API remains particulate in the gut and is excreted in faeces. Powder X-ray diffraction should show broad scattering rather than sharp diffraction lines; the presence of sharp hematite lines indicates over-drying or loss of the stabilizing organic fraction. The designation “Oral & Injectable” refers to two separate grades: an oral solid-dose powder and a sterile-development powder for injectable formulation screening. It does not imply that the approved oral phosphate-binder indication extends to parenteral administration. Published safety data for injectable sucroferric oxyhydroxide in humans are limited; approved parenteral iron products use different colloidal iron-carbohydrate complexes such as iron sucrose, ferric carboxymaltose, and low-molecular-weight iron dextran.

What release and in-process controls are applied to tablet and capsule manufacture?

Release characterization for oral solid-dose operations is directed toward powder flow, compression behavior, and blend uniformity. The iron assay is performed by redox titration after acid digestion rather than by direct colorimetric measurement, because the red-brown iron oxide matrix interferes with simple spectrophotometric methods. Loss on drying is determined per USP <731>, bulk and tapped density per USP <616>, and particle-size distribution by laser diffraction under ISO 13320:2020. The powder should be delumped through a conical mill fitted with a sieve screen between 0.8 mm and 1.0 mm before blending. Direct compression is feasible only when the API particle-size distribution is matched to the filler system; otherwise the dense iron-containing particles segregate. For tablet production, roller compaction followed by dry screening is preferred over aqueous wet granulation, because soluble binders can coat the oxyhydroxide surface and reduce phosphate binding. A granule size below 250 µm is typical for capsule filling and sachet uniformity; the acceptance range is established during process validation rather than taken from a single universal monograph.

On production-scale equipment, the main processing bottleneck for high inorganic load formulations is weight variation at the die table. Rotary tablet presses with 27 or more stations may require force feeders to maintain die fill because the dense API does not flow as readily as spray-dried lactose. The API’s high tapped density can create batch-to-batch weight variation if the hopper is not maintained above 50% fill; twin-screw feeding gives more reproducible mass flow than single-screw volumetric feeding for this material. Tablet friability should be monitored per USP <1216>; chewable tablets containing the oxyhydroxide may require hardness in the range where the tablet remains crumble-resistant during packaging but still fractures readily under chewing. Excipient selection must avoid phosphate-containing fillers such as dicalcium phosphate, because they would saturate binding sites before administration.

Granule and oral suspension processing shifts the control emphasis from raw API particle size to granule porosity, rewetting, and sedimentation after reconstitution. The API is practically insoluble; in a reconstituted suspension, the active surface must remain dispersed long enough to deliver a uniform dose. For suspension granules, dry granulation is preferable to a high-shear aqueous process because a water-soluble polysaccharide binder can coat the iron oxyhydroxide surface and reduce phosphate binding. If wet granulation cannot be avoided, the binder level should be minimized and the granulation endpoint determined by impeller torque rather than fixed water addition. The dried granules are milled through a slow-speed granulator and screened; the fraction retained above 250 µm may be reprocessed, while the fraction below 75 µm can increase dust and segregation during sachet filling. For capsule-filling operations, a hydrophobic lubricant sequence is preferred over prolonged magnesium stearate blending, because the iron oxyhydroxide surface can adsorb fatty acid salts and alter the phosphate-binding rate under pH conditions that model the upper small intestine.

Actual pharmacological positioning compared with sevelamer carbonate, lanthanum carbonate, and ferric citrate

Sucroferric oxyhydroxide differs from sevelamer carbonate in both chemistry and safety monitoring. Sevelamer carbonate is an anion-exchange resin that binds phosphate through protonated amine groups and also binds bile acids, thereby lowering LDL cholesterol; it contains no metal. Sucroferric oxyhydroxide is a metal-oxide surface binder and does not rely on resin hydration or counterion exchange. Compared with lanthanum carbonate, sucroferric oxyhydroxide is essentially non-absorbed, whereas lanthanum has a small but measurable systemic exposure and requires long-term tissue-accumulation monitoring. Compared with ferric citrate, which is a soluble ferric iron complex that can raise transferrin saturation and serum ferritin, sucroferric oxyhydroxide provides minimal absorbable iron and is not indicated for iron deficiency or anemia management. The absence of calcium in sucroferric oxyhydroxide avoids the hypercalcemia risk associated with calcium acetate and calcium carbonate binders. The labelled starting dose of the reference sucroferric oxyhydroxide product is 3 tablets/day; sevelamer carbonate labelled dosing commonly ranges from 3 to 6 tablets/day depending on the previous binder dose and serum phosphorus. Pill burden and chewability therefore differentiate these products in clinical use.

From a formulation standpoint, sevelamer carbonate is highly hygroscopic and requires dry granulation or roller compaction under controlled humidity; sucroferric oxyhydroxide also benefits from dry processing but has a higher density and can be dry-granulated with less moisture sensitivity than sevelamer. Lanthanum carbonate chewable tablets require taste-masking and carry bowel obstruction precautions; sucroferric oxyhydroxide chewable tablets typically require sweetener and flavor systems but no polymeric coating. Ferric citrate tablets are film-coated and hygroscopic; the active iron is intentionally more labile, so the formulation must protect against oxidation-reduction cycling. These differences affect tooling design, tablet hardness, and packaging barrier requirements.

Injectable presentation of sucroferric oxyhydroxide would require a separate sterile-development pathway because the oral-grade powder is not depyrogenated, sterile, or controlled for submicron particulate matter. If a parenteral dispersion is examined in a research setting, particulate matter must be controlled under USP <787> or USP <788>, bacterial endotoxin under USP <85>, and sterility under USP <71>. Terminal steam sterilization is likely to alter the sucrose-starch matrix and may reduce phosphate-binding capacity through partial dehydration or structural rearrangement of the oxyhydroxide surface; therefore aseptic processing or dry-powder irradiation would require independent validation. The product should not be co-formulated with phosphate-containing excipients in either oral or injectable preparations because this would consume binding capacity before administration. For oral-grade handling, the API is packed in double polyethylene liners inside fibre drums with desiccant; it should not be stored in areas where relative humidity rises above the release specification established for the packaging configuration. Dust control during weighing and milling is required because insoluble iron oxide dust is a nuisance respiratory particulate; local exhaust ventilation or contained transfer is used in production suites. Parenteral iron carbohydrate complexes are designed with a particle size below 50 nm and a stabilizing carbohydrate shell; sucroferric oxyhydroxide oral API is a microgranular powder and is not structurally equivalent to injectable iron colloids. No pharmacopeial monograph currently defines an injectable-grade sucroferric oxyhydroxide.